Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
نویسندگان
چکیده
منابع مشابه
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma. The initial report demonstrated non-inferior efficacy with subcutaneous versus intravenous bortezomib for the primary end point: overall response rate after four cycles of single-agent bortezomib. We report updated ...
متن کاملarsenic trioxide in patients with refractory multiple myeloma: a prospective, phase ii, single-arm study
multiple myeloma (mm) characterized by proliferation of plasma cells in bone marrow and production of monoclonal immunoglobulin's. recently, arsenic trioxide (ato), has been considered for treatment refractory mm. we assessed the safety and efficacy of ato for patients with refractory mm. a phase 2, study of arsenic trioxide was conducted in 12 mm patients, whose refractory to two standard ther...
متن کاملA phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients.
8515 Background: In MM patients VMP is superior to MP. In relapsed-refractory patients the 4 drug combination VMPT induced a high proportion of complete responses (CR). METHODS 500 newly diagnosed MM patients ≥ 65 years were randomly assigned to receive VMPT (N=247) or VMP (N=253). Patients were treated with nine 5-week cycles of VMPT (bortezomib 1.3 mg/m2 days 1, 8, 15, 22; melphalan 9 mg/m2...
متن کاملSubcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Renal impairment is a common presenting feature in multiple myeloma (MM) and an estimated 50% of patients are affected during the course of their disease. Moderate and/or severe renal impairment/failure is associated with poorer survival. Subanalyses of phase III studies in patients with previously untreated or relapsed/refractory MM, along with other studies and analyses, have demonstrated tha...
متن کاملRandomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
BACKGROUND The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies. METHODS Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2020
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon-2019-0431